KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Quest Diagnostics (DGX) Common Equity (2016 - 2025)

Quest Diagnostics (DGX) has disclosed Common Equity for 17 consecutive years, with $7.2 billion as the latest value for Q4 2025.

  • Quarterly Common Equity rose 5.24% to $7.2 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $7.2 billion through Dec 2025, up 5.24% year-over-year, with the annual reading at $7.2 billion for FY2025, 5.24% up from the prior year.
  • Common Equity hit $7.2 billion in Q4 2025 for Quest Diagnostics, down from $7.3 billion in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $7.3 billion in Q3 2025 to a low of $5.9 billion in Q4 2022.
  • Historically, Common Equity has averaged $6.6 billion across 5 years, with a median of $6.5 billion in 2023.
  • Biggest five-year swings in Common Equity: grew 19.06% in 2021 and later decreased 8.53% in 2022.
  • Year by year, Common Equity stood at $6.5 billion in 2021, then fell by 8.53% to $5.9 billion in 2022, then rose by 6.95% to $6.3 billion in 2023, then rose by 7.43% to $6.8 billion in 2024, then rose by 5.24% to $7.2 billion in 2025.
  • Business Quant data shows Common Equity for DGX at $7.2 billion in Q4 2025, $7.3 billion in Q3 2025, and $7.3 billion in Q2 2025.